Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.
Company facts
| Company | Adicet Bio, Inc. |
|---|---|
| Symbol | ACET |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $89.22M (Massive market data, 2026-09-10) |
| Employees | 102 |
| Country | United States |
| Website | https://www.adicetbio.com |
Trading — Adicet Bio, Inc.
| Last price | $9.52 |
|---|---|
| Change | -0.10% |
| Previous close | $9.53 |
| Day range | $9.38 – $9.80 |
| 50-day average | $8.80 |
| 200-day average | $8.07 |
| Average volume | 128,999 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $-10.57 |
|---|---|
| Price / book | 0.74 |
| Enterprise value / EBITDA | -0.58 |
| Debt / equity | 0.01 |
| Current ratio | 6.71 |
| Dividend yield | 0.00% |
| Free cash flow | -$84.97M |
| Cash ratio | 1.84 |
| Enterprise value | $56.88M |
Reported 2026-09-10
Earnings
| Report date | 2026-11-04 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | ($1.56) |
| Year-ago EPS | ($4.64) |
| Analyst estimates | 2 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ACET are on the IntelTrends dashboard.